Acer Therapeutics (ACER) 10-Q2011 Q1 Quarterly report

Filed: 6 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: advance, agent, analyze, ATM, back, bankruptcy, biotech, chemistry, closed, CMC, collateralized, commence, compelling, concurred, confident, consummated, corporate, cumulative, deducting, defined, developmental, differentiator, directly, dosing, efficiency, effort, endpoint, enhance, Europe, evidence, existing, explore, fact, February, feedback, flexibility, focused, half, III, immunotherapy, insurance, January, laboratory, law, maker, moderate, negatively, negotiated, nonqualified, optimized, pendency, pending, permit, permitted, perspective, pivotal, platform, pool, portion, preserving, proceed, procurement, rationale, reagent, recruit, reintroduced, relief, repurchase, resolved, retrospective, seek, selected, sell, senior, separable, separate, separately, settled, side, summed, tailored, therapy, transaction, transition, typically, underwriting, valuation, working

Removed: absolute, account, amortization, assay, atrophy, attacking, auction, auditor, August, autoimmune, autoreactive, balance, baseline, body, broadly, central, CIS, cleared, CNS, conducted, confirm, culture, decreased, directed, disability, doubt, enrolled, entered, entitled, entry, ess, evaluate, event, exclusive, experienced, expressed, feature, forgoing, formulation, free, gamma, granting, greater, harmful, human, identified, immunologic, immunology, immunosuppressive, implicated, important, improvement, inclusion, independent, individual, induce, involved, irradiation, islet, lease, leased, lesion, level, marked, match, measured, minimum, monocyte, Multicenter, nerve, neurologic, Notwithstanding, October, office, person, point, prevailing, Promissory, randomization, ranging, reactive, reactivity, receiving, remained, responsibility, Scale, score, security, sheath, showing, specific, stabilization, statistically, subgroup, succ, surface, sustained, tolerated, transient, unrestricted, volume, weakened, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ACER similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Opexa Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2011 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Neil K. Warma, President, Chief Executive Officer and Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

1.	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 6, 2011	By:	/s/ Neil K. Warma
		Neil K. Warma President and Chief Executive Officer (Principal Executive Officer) Acting Chief Financial Officer (Principal Financial and Accounting Officer)